Thrombospondin-1 (TSP1) can induce pro-inflammatory gene expression in MFs and MF-specific TSP1−/− mice showed reduced liver injury in experimental NAFLD, suggesting MF-specific TSP1-modulation as a therapeutic strategy [196]. Here, THBS1 is linked to metabolic dysfunction-associated steatotic liver disease.